Immunization of Flavivirus West Nile Recombinant Envelope Domain III Protein Induced Specific Immune Response and Protection against West Nile Virus Infection
Authors:
- 1 March 2007
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 178 (5) , 2699-2705
Abstract
The domain III of the West Nile virus (WNV) envelope glycoprotein (E) was shown to serve as virus attachment domain to the cellular receptor, and neutralizing Abs have been mapped to this specific domain. In this study, domain III of the WNV E protein (WNV E DIII) was expressed as a recombinant protein and its potential as a subunit vaccine candidate was evaluated in BALB/C mice. Immunization of WNV E DIII protein with oligodeoxynucleotides (CpG-DNA) adjuvant by i.p. injection was conducted over a period of 3 wk. The immunized mice generated high titer of WNV-neutralizing Abs. Murine Ab against WNV E DIII protein was also capable of neutralizing Japanese encephalitis virus. The IgG isotypes generated were predominantly IgG2a in the murine sera against the recombinant protein. Splenocyte cultures from the mice coadministrated with WNV E DIII protein and CpG secreted large amounts of IFN-γ and IL-2 and showed proliferation of T cells in the presence of WNV E DIII protein. Overall, this study highlighted that recombinant WNV E DIII protein delivered in combination with CpG adjuvant to mice generated a Th1 immune response type against WNV and can serve as a potential vaccine to prevent WNV infection.Keywords
This publication has 22 references indexed in Scilit:
- Expressions of Bovine IFN-γ and Foot-and-Mouth Disease VP1 antigen in P. pastoris and their effects on mouse immune response to FMD antigensVaccine, 2006
- An inactivated West Nile virus vaccine for domestic geese-efficacy study and a summary of 4 years of field applicationVaccine, 2005
- Chimeric Dengue 2 PDK-53/West Nile NY99 Viruses Retain the Phenotypic Attenuation Markers of the Candidate PDK-53 Vaccine Virus and Protect Mice against Lethal Challenge with West Nile VirusJournal of Virology, 2005
- Inhibition of West Nile virus entry by using a recombinant domain III from the envelope glycoproteinJournal of General Virology, 2005
- ChimeriVax-West Nile Virus Live-Attenuated Vaccine: Preclinical Evaluation of Safety, Immunogenicity, and EfficacyJournal of Virology, 2004
- Infectious Entry of West Nile Virus Occurs through a Clathrin-Mediated Endocytic PathwayJournal of Virology, 2004
- Solution Structure and Antibody Binding Studies of the Envelope Protein Domain III from the New York Strain of West Nile VirusJournal of Biological Chemistry, 2004
- Use of CpG oligodeoxynucleotides as immune adjuvantsImmunological Reviews, 2004
- CpG‐containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvantsEuropean Journal of Immunology, 1997
- The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolutionNature, 1995